22 results about "Asparaginase" patented technology

The invention relates to methods of inhibiting hair growth in a subject, the method comprises administering an inhibitor of lactic acid fermentation to the subject, wherein the inhibitor is selected from the group consisting of pyruvate dehydrogenase kinase inhibitor, desoxyrhapontigenin, a phosphofructokinases inhibitor, a thioredoxin-1 inhibitor, L- Asparaginase, a GLUT1 inhibitor, a glutaminase C inhibitor, a hexokinase inhibitor and an mTORCI and mTORC2 inhibitor. Also provided herein are compositions for inhibiting hair growth and methods of screening for inhibitors of hair growth.

The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.

The present disclosure provides an analyte sensor for use in detecting potassium. In certain embodiments, an analyte sensor of the present disclosure includes at least two asparagine-responsive active areas, where each asparagine-responsive active area includes an asparaginase that exhibits a particular potassium dependency. In certain embodiments, an analyte sensor of the present disclosure includes at least two aspartate-responsive active areas, where each aspartate-responsive active area includes an aspartate oxidase that exhibits a particular potassium dependency. The present disclosure further provides methods for monitoring potassium levels, e.g., in vivo potassium levels, using the disclosed analyte sensors.

2 Methods of Treatment with Asparaginase Abstract The invention relates to methods of treating diseases with L-asparaginase. Methods of Treatment with Asparaginase Abstract The invention relates to methods of treating diseases with L-asparaginase. 2 20 24 27 82 86 11 D ec 2 02 4 2 0 2 4 A b s t r a c t 2 0 2 4 2 7 8 2 8 6 1 1 D e c 2

The invention discloses a method for improving enzymolysis peculiar smell of dairy products and application, and belongs to the technical field of dairy product processing. The method comprises the following steps: carrying out enzymolysis on raw milk by using composite protease consisting of excision protease and asparaginase, carrying out secondary enzymolysis by using an alcohol-containing system, and finally inactivating the enzyme, so as to improve the enzymolysis odor of the dairy product. By adopting the compound enzyme preparation with a specific ratio and optimizing an alcohol-containing system and enzymolysis process conditions, undesirable flavors such as saponification flavor, grease rancidity flavor or bitter taste and the like which are easily generated in a single enzymolysis process are effectively avoided. The method is suitable for preparing the flavored dairy products.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

Described herein are methods and compositions for treating cancer. Aspects of the invention relate to determining if a biological sample obtained from a subject for GSK3α bodies (puncta), e.g., in response to asparaginase treatment, and administering to a subject having cancer an asparaginase and an agent that inhibits GSK3α to a subject who has been identified as forming GSK3α-positive bodies.

The present disclosure provides compositions and methods for treating cancer in a human subject comprising dosing a human subject with a monotherapy or combination therapy involving L-asparaginase. Combination therapies disclosed herein include combination therapies with functionalized or unfunctionalized L-asparaginase in combination with a BCL-XL inhibitor, a BCL-2 inhibitor, a CD20 inhibitor, an mTOR inhibitor, or another anticancer agent.

Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an asparaginase and an agent that inhibits GSK3ƒ. Another aspect of the invention relates to administering an asparaginase to a subject having cancer that comprises an inactivating mutation in GSK3ƒ.

The invention provides a method for preparing and separating L-asparaginic acid and a byproduct ammonium sulfate thereof by an enzyme method. The method comprises the following steps: step 1, reacting fumaric acid with ammonia to prepare an ammonium fumarate aqueous solution; and 2, continuously pumping the ammonium fumarate solution into a reactor filled with L-asparaginase resin particles, and carrying out a continuous flow circular reaction in the reactor. 3, after the reaction endpoint is detected, decolorizing the reaction solution, adding sulfuric acid to adjust the pH value, separating out L-asparaginic acid, and carrying out solid-liquid separation to obtain a solid and a mother solution; the L-asparaginase resin particles are prepared through the following steps that A, a strain is inoculated into a shake flask culture medium to be cultured, then the culture is gradually enlarged to the scale of a fermentation tank, centrifugation is conducted, and L-asparaginase solids are collected; and B, adding the L-asparaginase solid and the resin into water to obtain the L-asparaginase resin particles with the particle size of 5-8 mm. According to the method provided by the invention, the L-asparaginase resin particles can be recycled, and the enzyme fermentation liquid does not enter the L-asparaginic acid production liquid, so that the quality of the finished product is improved.

The invention discloses a method for improving sensory quality of raw milk by using composite enzymatic hydrolysis and application, and belongs to the technical field of dairy product processing. The method comprises the following steps: carrying out enzymolysis on raw milk by using compound protease consisting of excision protease and asparaginase, carrying out enzymolysis by using lipase, and finally inactivating the enzyme, so as to improve the sensory quality of the raw milk. According to the invention, the complex enzyme preparation with a specific ratio is adopted, and the enzymolysis process conditions are optimized, so that the bad flavors such as saponification flavor, grease rancidity flavor or bitter taste which are easily generated in a single enzymolysis process are effectively avoided. According to the method, the sensory quality of the raw milk can be remarkably improved, so that the raw milk has a complex and rich taste similar to that of fermented milk. The method is suitable for preparing the flavored dairy products.

Embodiments of the present invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized, storage-stable composition. In some instances, the lyophilized composition includes one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods for making the composition. The composition finds use in a variety of applications, including, for example, treating a neoplastic condition in a subject.

The invention relates to application of asparaginase in preparation of anti-inflammatory drugs, and belongs to the technical field of biological medicines. The invention discovers and discloses a new application of asparaginase in preparation of anti-inflammatory drugs for the first time. Experiments prove that the asparaginase affects the combination of asparaginase and an important linker molecule TBK1 in innate immunity by reducing the content of asparaginase in cells; according to the present invention, the asparaginase is used as the anti-inflammatory drug, and further influences the aggregation and the trans-self-phosphorylation of TBK1, such that the kinase activity of TBK1 is reduced, and the activation of the TBK1 downstream signal channel is inhibited, such that the generation of IFN-beta in the macrophage after DNA virus and RNA virus infection is significantly reduced, the replication of DNA and RNA viruses in the macrophage is promoted, and the specific anti-inflammatory effect of the asparaginase is proved, and the asparaginase can be used for preparing the anti-inflammatory drug.

The application relates to the technical field of genetic engineering, in particular to application of reducing expression amount of L-asparaginase in improving plant antiviral ability and antiviral plant material. The application finds that 126 kDa protein of PMMoV virus directly targets L-asparaginase (LA), manipulates amino acid metabolism by enhancing the enzyme activity of LA to benefit the survival of the virus, and the plant antiviral ability can be improved by reducing the expression amount of L-asparaginase. The application establishes the connection between virus infection and host amino acid metabolism, and provides a new application perspective for preventing and treating plant viruses.

The present invention relates to a liquid composition comprising: a polyalkylene oxide-asparaginase at a concentration of 750 IU per mL of the composition; dibasic sodium phosphate at a concentration of 0.5 to 0.6% by weight; monobasic sodium phosphate at a concentration of 0.1 to 0.2% by weight; and sodium chloride at a concentration of 0.8 to 1.0% by weight, wherein the polyalkylene oxide-asparaginase comprises an asparaginase covalently linked to a polyalkylene oxide group that is a polyethylene glycol, wherein the polyalkylene oxide group is covalently linked by a carbamate linker to the asparaginase, wherein the carbamate moiety originates from a succinimidyl carbonate (SC) linker

Provided herein are methods of treating asparaginase-induced pancreatitis with an intracellular calcium signaling inhibitor in pediatric patients. The intracellular calcium signaling inhibitor can be administered alone or in combination with an additional therapeutic agent. In some aspects, the additional therapeutic agent is an asparaginase-containing agent. The methods of the present disclosure show effective treatment that, among other benefits, significantly reduced the time pediatric patients spent in the hospital, an important benefit in a patient population that frequently suffers from severe disease.

Aspects of the invention include polyalkylene oxide-asparaginase compositions. In some instances, the composition is a lyophilized storage stable composition. In some instances, the lyophilized compositions include one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition in a subject.

A pharmaceutical preparation including asparaginase characterised in that the asparaginase is encapsulated or contained within bacterial extracellular vesicles (BEVs).

The invention relates to the technical field of nano material synthesis, in particular to an asparaginase organic-inorganic hybrid nanocrystal and a preparation process thereof, and a coated asparaginase particle and a preparation process thereof. The preparation process of the asparaginase organic-inorganic hybrid nanocrystal comprises the following preparation step: synthesizing the organic-inorganic hybrid nanocrystal (NCs) consisting of asparaginase and copper phosphate (Cu3 (PO4) 2.3 H2O) by adopting a coprecipitation method. The prepared nanocrystal is combined with a layer-by-layer assembly technology to prepare the core-shell structure particle which takes the nanocrystal as a core and takes a biocompatible polymer layer (chitosan / chitosan oligosaccharide and polydopamine) as a shell, so that the prepared particle not only retains the performance of enzyme specific recognition and asparagine hydrolysis, but also can be used for preparing the biocompatible polymer layer (chitosan / chitosan oligosaccharide and polydopamine). And the defects of poor stability and high immunogenicity of the free asparaginase are effectively overcome to a certain extent.

The present application relates to food additives, disclose a kind of acrylamide inhibitor and its application, the method for reducing acrylamide in food.The acrylamide inhibitor contains mixed preservation or each independent preservation asparaginase and ammonium containing hydroxyl group organic acid, relative to 1 mass fraction of the asparaginase, the content of the ammonium containing hydroxyl group organic acid is 1-8 mass fraction.The acrylamide inhibitor can effectively reduce the content of acrylamide in fried food, and component is simple.

The present invention relates to a novel fusion protein in which a monobody specifically bidning to a tumor antigen is linked to L-asparaginase for treating solid cancer more efficiently, and a use thereof, paticularly to a novel fusion protein comprising a recombinant monobody which specifically binds to clareticulin and an L-asparaginase linked to the C-terminus of the recombinant monobody, wherein the recombinant monobody has a peptide that specifically binds to the calreticulin inserted into at least one of the BC loop and the FG loop of human fibronectin domain III (Fn3) as an asparaginase-based novel anticancer agent targeting tumor antigen whose drug delivery efficacy to tumor tissue is enhanced.